Clinical Trials Logo

Solid Neoplasm clinical trials

View clinical trials related to Solid Neoplasm.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01552356 Active, not recruiting - Solid Neoplasm Clinical Trials

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

Start date: March 19, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in treating patients with solid tumors that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or does not respond to treatment (refractory). Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients receiving pazopanib hydrochloride may help doctors learn more about the effects of the body on the drug. It may also help doctors understand how well patients respond to treatment.

NCT ID: NCT00740805 Active, not recruiting - Solid Neoplasm Clinical Trials

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Start date: August 18, 2008
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib, cyclophosphamide, and doxorubicin hydrochloride when given together in treating patients solid tumors or non-Hodgkin lymphoma that has spread to other areas of the body or cannot be removed by surgery. Veliparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, cyclophosphamide, and doxorubicin hydrochloride may kill more cancer cells.